507 related articles for article (PubMed ID: 26308799)
1. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.
Bononi A; Napolitano A; Pass HI; Yang H; Carbone M
Expert Rev Respir Med; 2015 Oct; 9(5):633-54. PubMed ID: 26308799
[TBL] [Abstract][Full Text] [Related]
2. [Molecular heterogeneity of malignant pleural mesotheliomas].
Tranchant R; Montagne F; Jaurand MC; Jean D
Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
[TBL] [Abstract][Full Text] [Related]
3. Malignant Mesothelioma and Its Non-Asbestos Causes.
Attanoos RL; Churg A; Galateau-Salle F; Gibbs AR; Roggli VL
Arch Pathol Lab Med; 2018 Jun; 142(6):753-760. PubMed ID: 29480760
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
5. [Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects].
Mohr S; Keith G; Rihn B
Bull Cancer; 2005 Nov; 92(11):959-76. PubMed ID: 16316830
[TBL] [Abstract][Full Text] [Related]
6. Peritoneal mesothelioma: the site of origin matters.
Kindler HL
Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
[TBL] [Abstract][Full Text] [Related]
7. [microRNAs as biological indicators of environmental and occupational exposure to asbestos].
Minoia C; Sturchio E; Porro B; Ficociello B; Zambelli A; Imbriani M
G Ital Med Lav Ergon; 2011; 33(4):420-34. PubMed ID: 22452101
[TBL] [Abstract][Full Text] [Related]
8. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
9. Contemporary approaches in the investigation and treatment of malignant pleural mesothelioma.
Pass HI
Chest Surg Clin N Am; 1994 Aug; 4(3):497-515. PubMed ID: 7953481
[TBL] [Abstract][Full Text] [Related]
10. Statement on malignant mesothelioma in the United Kingdom.
British Thoracic Society Standards of Care Committee
Thorax; 2001 Apr; 56(4):250-65. PubMed ID: 11254815
[No Abstract] [Full Text] [Related]
11. Non-occupational exposure to asbestos and malignant mesothelioma in females.
Vianna NJ; Polan AK
Lancet; 1978 May; 1(8073):1061-3. PubMed ID: 77365
[TBL] [Abstract][Full Text] [Related]
12. A catalogue of treatment and technologies for malignant pleural mesothelioma.
Schunselaar LM; Quispel-Janssen JM; Neefjes JJ; Baas P
Expert Rev Anticancer Ther; 2016; 16(4):455-63. PubMed ID: 26943000
[TBL] [Abstract][Full Text] [Related]
13. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
14. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Carbone M; Adusumilli PS; Alexander HR; Baas P; Bardelli F; Bononi A; Bueno R; Felley-Bosco E; Galateau-Salle F; Jablons D; Mansfield AS; Minaai M; de Perrot M; Pesavento P; Rusch V; Severson DT; Taioli E; Tsao A; Woodard G; Yang H; Zauderer MG; Pass HI
CA Cancer J Clin; 2019 Sep; 69(5):402-429. PubMed ID: 31283845
[TBL] [Abstract][Full Text] [Related]
15. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in relapsed mesothelioma.
Brosseau S; Dhalluin X; Zalcman G; Scherpereel A
Immunotherapy; 2018 Feb; 10(2):77-80. PubMed ID: 29260624
[No Abstract] [Full Text] [Related]
17. Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
Nuvoli B; Galati R
Mol Cancer Ther; 2013 Jun; 12(6):844-52. PubMed ID: 23729401
[TBL] [Abstract][Full Text] [Related]
18. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
Dragon J; Thompson J; MacPherson M; Shukla A
J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
[TBL] [Abstract][Full Text] [Related]
19. Miracle mineral or mesothelioma: cancer and asbestos in the USA.
Lucas C
Lancet Oncol; 2018 Jul; 19(7):868. PubMed ID: 30084369
[No Abstract] [Full Text] [Related]
20. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]